Hiuchi Pharma Co., Ltd

Hiuchi Pharma Inc. - Executive Summary

Company Overview:

• A biotech startup established in October 2025, developing a first-in-class small molecule platform targeting TRPC3/C6 channels.

• Founded by global pioneers in TRP channel research and led by highly experienced industry experts.

Lead Program (L862) & Status:

• An oral TRPC3/C6 dual inhibitor targeting Pulmonary Arterial Hypertension (PAH) as its primary indication.

• Currently Phase 1-ready (IND-ready), having successfully completed all required GLP toxicity studies and PMDA formal consultations with no outstanding issues.

Competitive Advantage:

• Acts as a disease-modifying therapy that directly inhibits and potentially reverses fibroproliferative vascular remodeling, unlike current standard-of-care vasodilator therapies.

• Provides high selectivity and a clean safety profile, avoiding the systemic side effects associated with broad-acting competitors like Sotatercept.

Intellectual Property:

• Foundational composition of matter patents (substance patents) are already granted in the US, Europe, Japan, and China.

• Clean Freedom to Operate (FTO) is secured through exclusive worldwide in-licensing agreements with the originating universities.

Market Opportunity & Exit Strategy:

• The PAH market is projected to reach $13.3 billion by 2033, with L862's estimated global peak sales reaching up to $4.3 billion.

• The strategic goal is to execute a corporate M&A buyout following global Phase 2a clinical proof-of-concept (POC), targeting a transaction value of $300 million or more.

Fundraising Status:

• Currently seeking a Series A financing round of $7 million to execute Phase 1 clinical trials and formulation development in Japan.